Singh Biotechnology (SBT)

About Singh Biotechnology (SBT)

Singh Biotechnology (SBT) is a start-up biotech organization established in 2014 which is in the business of discovering and developing unique and proprietary therapeutic single domain antibodies (sdAbs) for the treatment of a variety of cancers, autoimmune and ophthalmic diseases by leveraging our novel technology platform. Using this technology platform, SBT has been able to generate therapeutic sdAbs that specifically target intracellular molecules of interest, which are mutated, over expressed, or play an important role in the pathogenesis of disease(s). Currently SBT has one pre-IND stage program for triple negative breast cancer (TNBC) and several programs in various stages of pre-clinical development for inflammatory bowel disease (IBD), age-related macular degeneration (ADM), rheumatoid arthritis (RA), psoriasis, prostate cancer, acute myeloid leukemia (AML), sarcoma, and glioblastoma. SBT is targeting to file an IND for TNBC in early 2017. Singh Biotechnology is a privately held company headquartered in Tampa, Florida.
YEAR FOUNDED:
2014
LEADERSHIP:
Founder & CEO: Sunanda Singh, MD, PhD
Chairman of Scientific Advisory Board: Hector J. Gomez, MD, PhD
Vice President of Research: Ashu Parihar
Business Development: Ameeta Patel, MBA
Director of Research and Drug Development: Robin Meray Patel, PhD
Director of Pharmacology & Dermatologic Research: Utpal K. Patel, MD, PhD
Director of Clinical Dermatology: Anjali H. Singh, MD